

Stanford



Millie Das

Clinical Associate Professor, Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr

MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-9113

Bio

BIO

Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and also leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.

CLINICAL FOCUS

- Thoracic Oncology
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chief, Oncology, VA Palo Alto Health Care System, (2015- present)
- Associate Program Director, Oncology Fellowship, Stanford University, (2015- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, International Association for the Study of Lung Cancer (IASLC) (2009 - present)
- Member, American Society of Clinical Oncology (ASCO) (2008 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2001) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2011)

- Residency: Stanford University Hospital -Clinical Excellence Research Center (2007) CA
- Internship: Stanford University Hospital -Clinical Excellence Research Center (2005) CA
- Medical Education: University of Massachusetts Medical Center (2004) MA

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- MAGE A10####T for Advanced NSCLC, Recruiting
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor, Recruiting
- Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer, Recruiting
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer, Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors, Not Recruiting
- A Phase 1/2 Study to Evaluate MEDI4736, Not Recruiting
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges, Not Recruiting
- A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Not Recruiting
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026), Not Recruiting
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer, Not Recruiting
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer, Not Recruiting
- Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC, Not Recruiting
- PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients, Not Recruiting
- Phase 2 Etirinecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer, Not Recruiting
- Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer, Not Recruiting
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer, Not Recruiting
- Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination, Not Recruiting
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010], Not Recruiting

Publications

PUBLICATIONS

- **Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes**
Moding, E. J., Nabet, B. Y., Liu, Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Binkley, M. S., He, J., Qiao, Y., Xu, T., Yao, L., Gandhi, S., Liao, et al
ELSEVIER SCIENCE INC.2019: S113
- **Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Diehn, M., Wakelee, H. A.
2019; 134: 42–45
- **Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Wakelee, H. A., Diehn, M.
2019

- **Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer.** *Lung cancer (Amsterdam, Netherlands)*
Harris, J. P., Nwachukwu, C., Qian, Y., Pollom, E., Loo, B. W., Das, M., Diehn, M.
2018; 124: 76–85
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.** *Cancer chemotherapy and pharmacology*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer**
Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., Newman, A. M., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H., Das, et al
ELSEVIER SCIENCE INC.2018: E1–E2
- **Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer**
Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., Say, C., Carter, J. N., Walters, S., Becker, H. R., Das, M., Padda, S., Loo, et al
ELSEVIER SCIENCE INC.2017: S20–S21
- **Patterns of Care and Health Disparities for Patients With Stage I Non-small Cell Lung Cancer in the US**
Harris, J. P., Nwachukwu, C. R., Loo, B. W., Das, M., Diehn, M.
ELSEVIER SCIENCE INC.2017: E399
- **Diagnosis and Treatment of Adenocarcinomas and Squamous Cell Carcinomas of the Lung.** *Journal of the advanced practitioner in oncology*
Das, M., Tisch, A. H.
2017; 8 (3): 267–72
- **ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.** *Journal of thoracic oncology*
Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., Wakelee, H. A., Neal, J. W.
2017
- **Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction** *LUNG CANCER*
Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., Wakelee, H. A.
2015; 89 (3): 280-286
- **Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.** *Translational lung cancer research*
Das, M., Wakelee, H.
2014; 3 (6): 397-399
- **A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)**
Neal, J. W., Wakelee, H. A., Feliciano, J., Goldberg, S. B., Morgensztern, D., Das, M., Heist, R., Lennes, I., Muzikansky, A., Edelman, M. J., Gettinger, S. N., Sequist, L. V.
AMER SOC CLINICAL ONCOLOGY.2014
- **Anti-angiogenic Agents in Metastatic NSCLC** *LUNG CANCER,4TH EDITION*
Das, M., Wakelee, H., Roth, J. A., Hong, W. K., Komaki, R. U., Tsao, A. S., Chang, J. Y., Blackmon, S. H.
2014: 527–40
- **ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION**
Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., Wakelee, H. A.
LIPPINCOTT WILLIAMS & WILKINS.2013: S1185–S1186
- **VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS**
Nguyen, K. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., Burt, B., Tisch, A., Pagtama, J., Zehnder, J., Berry, G., Wakelee, H. A., Anh-Hoa Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S208–S209

- **PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER**
Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, et al
LIPPINCOTT WILLIAMS & WILKINS.2013: S1324
- **A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.** *Clinical lung cancer*
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., Cherry, A., Wakelee, H. A.
2013; 14 (5): 592-595
- **A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab** *JOURNAL OF THORACIC ONCOLOGY*
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., Wakelee, H. A.
2013; 8 (2): E17-E18
- **Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study** *JOURNAL OF THORACIC DISEASE*
Das, M., Wakelee, H.
2012; 4 (6): 558-561
- **Angiogenesis inhibitors.** *Journal of thoracic oncology*
Das, M., Wakelee, H.
2012; 7 (16): S397-8
- **BIOMARKERS FOR ANTI-ANGIOGENIC THERAPY**
Das, M., Wakelee, H.
ELSEVIER SCIENCE INC.2012: S442-S443
- **ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.** *Lung cancer*
Das, M., Riess, J. W., Frankel, P., Schwartz, E., Bennis, R., Hsieh, H. B., Liu, X., Ly, J. C., Zhou, L., Nieva, J. J., Wakelee, H. A., Bruce, R. H.
2012; 77 (2): 421-426
- **Angiogenesis Inhibitors** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2011; 6 (11): S1801-S1802
- **Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer** *CLINICAL LUNG CANCER*
Das, M., Donington, J. S., Murphy, J., Kozak, M., Eclov, N., Whyte, R. I., Hoang, C. D., Zhou, L., Le, Q., Loo, B. W., Wakelee, H.
2011; 12 (5): 280-285
- **Stage IIIB and IV NSCLC: Primary Therapy** *LUNG CANCER: A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT*
Das, M., Wakelee, H., Kernstine, K., Reckamp, K.
2011: 183-95
- **Vascular Disrupting Agents** *JOURNAL OF THORACIC ONCOLOGY*
Das, M., Wakelee, H.
2010; 5 (12): S482-S483
- **Alternatives to Surgery for Early Stage Non-Small Cell Lung Cancer-Ready for Prime Time?** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Das, M., Abdelmaksoud, M. H., Loo, B. W., Kothary, N.
2010; 11 (1-2): 24-35